BioSpace News Archive

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced the appointment of Jeffrey Rosenfeld, Ph.D., as its new Executive Director, Genomics and Bioinformatics.

EyePoint Pharmaceuticals, Inc. today announced that it has entered into a loan agreement providing for senior secured credit facilities in the aggregate amount of $45 million with Silicon Valley Bank to replace its existing credit facility with CRG Servicing LLC (CRG).

Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, reported fourth quarter and full year 2021 financial results and highlighted recent achievements and developments.

AIM ImmunoTech Inc. announced that oncology experts from Roswell Park Comprehensive Cancer Center will present findings from two ongoing clinical studies involving an AIM ImmunoTech Inc. drug candidate, Ampligen® at the American Association for Cancer Research Annual Meeting 2022, being held April 8-13, 2022, in New Orleans, Louisiana.

Antengene Corporation Limited today announced the publication of abstracts for five posters that will be presented during the upcoming 2022 American Association for Cancer Research Meetings (AACR 2022), taking place from April 8th to April 13th in New Orleans via in person or virtual attendance.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company’s senior management team will participate in a fireside chat at the Barclays Global Healthcare Conference.

As part of an ongoing multi-center study, Fluidx Medical released additional information on treating tumors including a highly vascularized metastatic renal cell carcinoma with the GPX Embolic Device.

Compugen Ltd. today announced that management will present at the Oppenheimer 32nd Annual Global Healthcare Conference (virtual), on Wednesday, March 16, 2022 at 11:20 am ET .

REGENXBIO Inc. announced it will participate in the following upcoming investor conferences.

Bristol Myers Squibb announced its participation in the following investor conferences on Wednesday, March 16, 2022: